A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
[Phase I part] To investigate the safety, tolerability, and pharmacokinetics of MT-2111
monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In
addition, the dose to be used in the Phase II part will be confirmed.
[Phase II part] To evaluate the efficacy of MT-2111 monotherapy in patients with
relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.